Abstract 225P
Background
Prostate cancer ranges from indolent to aggressive, with 10–20% of patients developing metastases. Immune cell interactions in the tumor microenvironment facilitate growth. This study aimed to characterize circulating immune cells in patients with oligometastatic (OMPC) and plurimetastatic prostate cancer (PMPC).
Methods
This retrospective cohort study included individuals with metastatic prostate cancer (mPC). Patients were classified into two groups: OMPC (five or fewer lesions in bone and/or lymph nodes via CT or bone scans), and PMPC, those not meeting OMPC criteria. Demographic data and immune cell subsets were collected at admission. After blood collection, peripheral blood mononuclear cells were isolated, and flow cytometry assessed various immune populations (γδ T cells, αβ T cells, Tregs, memory T cells, effector T cells, NK cells, NKT cells, B cells, myeloid cells, and monocytes) and cytokines (TNF-α, IFN-γ, IL-17). The Mann–Whitney U test was used for comparisons, with p ≤ 0.05 considered significant.
Results
43 patients were identified, with a median age of 64 years (50-80). 17 patients (39.5%) had OMPC and 26 (60.5%) had PMPC. 16 patients (37.2%) presented with de novo mPC. Bone was the most common metastatic site in both groups. Most patients (67.4%, n=29) received hormone therapy (HT) as first-line treatment , while 9 patients (20.9%) received chemotherapy plus HT. An increase in γδ2+ T cells (p=0.048) was noted in the OMPC group. There was a trend toward increased levels of γδ2+ expressing IFN-γ (p=0.066) in PMPC patients.
Conclusions
A significant increase in γδ2+ T cells was observed in OMPC. These cells are critical for immune modulation. Elevated levels in OMPC subgroup may indicate an active immune response, potentially providing a protective effect against tumor progression in this subgroup. Conversely, PMPC patients showed a trend toward increased IFN-γ expression in γδ2+ T cells (p=0.066). While these cells can produce IFN-γ, those in OMPC may be less activated, limiting their effectiveness and suggesting an immune escape mechanism. This study has limitations; results are exploratory and require confirmation in a larger cohort. We plan to validate the differences in γδ2+ T cells and IFN-γ expression in an independent group.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
88P - Utilisation of the ESMO-MCBS in prioritising immune-checkpoint inhibitors for a WHO model list of essential medicines application
Presenter: Mario Csenar
Session: Poster Display session
89P - Safety and efficacy of rechallenge with immune checkpoint inhibitors in advanced solid tumor: A systematic review and meta-analysis
Presenter: Huijun Xu
Session: Poster Display session
90P - Meta-analysis of hypophysitis incidence in melanoma patients treated with immune checkpoint inhibitors
Presenter: Vincas Urbonas
Session: Poster Display session
91P - Territorial disparities in the use of hospitalization at home for immune checkpoint inhibitors infusion in France between 2021 and 2022
Presenter: Anne Claire Toffart
Session: Poster Display session
92P - An investigation on the differences between the pre-treatment nutritional and immunological status of nasopharyngeal carcinoma patients and the healthy population
Presenter: Qiao He
Session: Poster Display session
93P - Pseudoprogression in immunotherapy: Illusion or reality? P-PIT study
Presenter: Amelie Toulet
Session: Poster Display session
94P - Real-world characteristics, treatments and healthcare recourse utilization (HCRU) of patients (pts) with advanced/metastatic non-small cell lung cancer (mNSCLC) managed with first line (1L) immuno-oncology (IO) strategies in Greece: The IO-HORIZON study
Presenter: Dimitrios Ziogas
Session: Poster Display session
95P - Quality of life (QoL) and care pathway in patients with durable response to immune checkpoint inhibitors (ICI-DR) for advanced or metastatic non-small cell lung cancer (NSCLC) or melanoma: QUALICI study
Presenter: Nicolas Girard
Session: Poster Display session
96P - Comparative cardiovascular risks of PD-1 vs. PD-L1 inhibitors: A meta-analysis of incidence and severity of cardiotoxicity
Presenter: Mohammedbaqer Al-Ghuraibawi
Session: Poster Display session
Resources:
Abstract
97P - Cardiac risk stratification and serial monitoring during immune checkpoint inhibitor therapy: Prospective real-world experience
Presenter: James Knott
Session: Poster Display session